Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictive Biomarker for Renal Failure Stratification and Urinary Tract Infections in Hemodialysis Patients

Background: Hemodialysis (HD) is a vital therapeutic intervention for patients with renal failure; however, it is also associated with various health complications, including urinary tract infections (UTIs), which significantly increase the risk of adverse outcomes, This study assessed the role of soluble urokinase plasminogen activator receptor (suPAR) in predicting disease progression, infection severity, and kidney dysfunction in renal failure patients (with/without UTIs) versus controls, determining its potential for early diagnosis and clinical management in hemodialysis populations. Methods: A case-control study was conducted on 90 subjects and compared with 30 healthy controls at Al-Hussein Teaching Medical City Hospital between October 2024 and January 2025. Participants were divided into three groups: Group I included 30 patients with UTI not on hemodialysis; Group II included 30 patients with renal failure and UTI; and Group III included 30 patients with renal failure without UTI. Bacterial pathogens were identified using the VITEK 2 Compact System, and concentrations of suPAR were measured using the sandwich ELISA technique. Results: The prevalence of UTI was significantly higher in females, with E. coli being the most common pathogen. Overall, suPAR levels were markedly elevated in patients with renal failure, both with and without UTI, compared to those in the UTI and control groups. Conclusions: suPAR demonstrated high sensitivity, specificity, and predictive values, suggesting its reliability as a biomarker for early diagnosis and clinical monitoring of renal dysfunction and associated infections. It may serve as a dependable biomarker for renal failure patients and holds promise for diagnostic and prognostic use in clinical settings. Key words: Soluble urokinase plasminogen activator receptor (suPAR), Hemodialysis. Renal failure, UTI

Authors

Publication Details

Journal
Karbala journal of medicine.
Published
2025-06-30
DOI
https://doi.org/10.70863/karbalajm.v18i1.3853
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictive Biomarker for Renal Failure Stratification and Urinary Tract Infections in Hemodialysis Patients

Ali Jalil Ali Alyassery, Ahmed Hasen Kaser Alkarewy, Karbala journal of Medicine Manager, Ahmed.hassen s.uokerbala.edu.iq
Karbala journal of medicine.
Dialysis and Renal Disease Management
article

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictive Biomarker for Renal Failure Stratification and Urinary Tract Infections in Hemodialysis Patients

Ali Jalil Ali Alyassery, Ahmed Hasen Kaser Alkarewy, Karbala journal of Medicine Manager, Ahmed.hassen s.uokerbala.edu.iq
article en

Abstract

Background: Hemodialysis (HD) is a vital therapeutic intervention for patients with renal failure; however, it is also associated with various health complications, including urinary tract infections (UTIs), which significantly increase the risk of adverse outcomes, This study assessed the role of soluble urokinase plasminogen activator receptor (suPAR) in predicting disease progression, infection severity, and kidney dysfunction in renal failure patients (with/without UTIs) versus controls, determining its potential for early diagnosis and clinical management in hemodialysis populations. Methods: A case-control study was conducted on 90 subjects and compared with 30 healthy controls at Al-Hussein Teaching Medical City Hospital between October 2024 and January 2025. Participants were divided into three groups: Group I included 30 patients with UTI not on hemodialysis; Group II included 30 patients with renal failure and UTI; and Group III included 30 patients with renal failure without UTI. Bacterial pathogens were identified using the VITEK 2 Compact System, and concentrations of suPAR were measured using the sandwich ELISA technique. Results: The prevalence of UTI was significantly higher in females, with E. coli being the most common pathogen. Overall, suPAR levels were markedly elevated in patients with renal failure, both with and without UTI, compared to those in the UTI and control groups. Conclusions: suPAR demonstrated high sensitivity, specificity, and predictive values, suggesting its reliability as a biomarker for early diagnosis and clinical monitoring of renal dysfunction and associated infections. It may serve as a dependable biomarker for renal failure patients and holds promise for diagnostic and prognostic use in clinical settings. Key words: Soluble urokinase plasminogen activator receptor (suPAR), Hemodialysis. Renal failure, UTI

Karbala journal of medicine.Vol. 18(1)
Openalex Percentile: Top 80%
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictive Biomarker for Renal Failure Stratification and Urinary Tract Infections in Hemodialysis Patients — Ali Jalil Ali Alyassery, Ahmed Hasen Kaser Alkarewy, et al. · Karbala journal of medicine. (2025) | TGRS Research Map | TGRS